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Aggressive B-cell lymphomas (ABLs) are a group of B-cell
malignancies, that is, a relatively common form of cancer
across the world. This issue on aggressive B-cell lymphomas
compiles 12 exciting manuscripts, most of which are very
meticulously performed reviews of the available current
literature.
Three areas of lymphoma pathology and biology that
are leading to a greater understanding of relatively recently
defined entities are discussed. These include anaplastic
lymphoma kinase (ALK)-positive large B-cell lymphoma
(ALK+ LBCL), and the so-called grey zone lymphomas
or lymphomas with intermediate features and the post-
transplant lymphoproliferative disorders. ALK+ LBCL are
characterised by gene rearrangement involving clathrin
and ALK genes (t(2;17)(p23;q23)). Grey zone lymphomas
include two unclassifiable B-cell lymphomas, one with
features intermediate between diﬀuse large B-cell lymphoma
(DLBCL) and classical Hodgkin lymphoma (cHL) and the
second with features intermediate between DLBCL and
Burkitt lymphoma (BL).
The biology of common lymphomas is addressed in two
manuscripts. M. Rossi et al. review the current literature
on molecular subsets of DLBCL, the distinction between
DLBCL and BL, and gene expression characteristics of the
grey zone lymphomas. This paper is accompanied by M.
Cacciatore et al.’s manuscript that explores the importance
of the microenvironment in lymphoma biology.
Two of the manuscripts deal with those aspects of
endemic BL pathogenesis that have hitherto not been
explored in great depth. The paper by S. Mannucci et al.
explore the possibility of Euphorbia tirucalli acting as a
cofactor in BL. They show that, in lymphoblastoid cell lines,
E. tirucalli can modulate the EBV latency genes, result in
polysomy for chromosome 8, and cause upregulation of c-
MYC. Furthermore, Dr. C. van den Bosch raises question
about a possible role for RNA viruses in the pathogenesis of
BL.
Dr. I. Magrath reviews the evolution of BL treatment
in Africa—from cyclophosphamide monotherapy to mul-
tiagent combination chemotherapy including central ner-
vous system prophylaxis using combinations of cyclophos-
phamide, vincristine, prednisone, and methotrexate. He also
highlights the benefits of collaboration between resource-
rich and resource-poor settings. P. Vishnu and D. M.
Aboulafia review how the treatment of HIV-associated
lymphomas has evolved since the introduction of highly
active antiretroviral therapy (HAART). The use of rituximab,
in conjunction with multiagent chemotherapy, and where
required high-dose chemotherapy (HDCT) and autologous
stem cell rescue (ASCT) have all contributed to the success
of treating HIV lymphomas. Treatment of ABL is further
reviewed in two paper—one on ASCT in DLBCL and the
other on novel therapies by K. Foon et al. To complete
the issue, S. Donnou reviews the currently available murine
models useful for studying lymphomagenesis, the lymphoma
microenvironment, and the eﬃcacy of new therapies.
By compiling these paper, we hope to enrich our readers
and researchers with respect to these particularly common,
yet usually highly treatable aggressive B-cell malignancies.
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